Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative pathogen of
the coronavirus disease 2019 (COVID-19), has caused more than 179 million infections and …

The emergence and rapid global spread of the new Delta and, more recently, Omicron
variants of SARS-CoV-2 pose a daunting public health emergency. Being an RNA virus, the …

ABSTRACT Background SARS-CoV-2 mRNA vaccines have proven high efficacy, however,
limited data exists on the duration of immune responses and their relation to age and side …

Background Large-scale vaccination against COVID-19 is being implemented in many
countries with CoronaVac, an inactivated vaccine. We aimed to assess the immune …

Antibodies produced by antibody-secreting plasma cells (ASCs) underlie multiple forms of
long-lasting immunity. Here we examined the mechanisms regulating ASC turnover and …

SARS-CoV-2 inactivated vaccines have shown remarkable efficacy in clinical trials,
especially in reducing severe illness and casualty. However, the waning of humoral …

B cells secrete antibodies and mediate the humoral immune response, making them
extremely important in protective immunity against SARS-CoV-2, which caused the …

Summary Infection with SARS‐CoV‐2, the etiology of the ongoing COVID‐19 pandemic, has
resulted in over 450 million cases with more than 6 million deaths worldwide, causing global …

Two years after the appearance of the SARS-CoV-2 virus, the causal agent of the current
global pandemic, it is time to analyze the evolution of the immune protection that infection …

Background Large-scale vaccination is being implemented globally with CoronaVac, an
inactivated vaccine against coronavirus disease 2019 (COVID-19). Immunogenicity and …